OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
A legfontosabb adatok
- Ki végzi
- Op-T LLC
- Hol
- Denver és Valhalla (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 26 fő, tervezett
- Kezdés
- 2026. márc. 9.
- Várható befejezés
- 2027. márc.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- OPT101
- Placebo
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (20)A regiszter feltételeinek elrejtése
Ki vehet részt
- Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed)
- ≥18 years old
- Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:; respiratory rate > 30 breaths/min; fever (> 38.0°C or > 100.4° F); leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3); adults ≥ 70 years of age; altered mental status with no other recognized cause; AND at least 1 of the following:; New onset of purulent sputum or change in character of sputum or increased respiratory secretions; New onset or worsening cough, or dyspnea, or tachypnea; Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300; recorded on one episode
- Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula/mask or heated high flow nasal cannula oxygen
- Females of child-bearing potential who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:; Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose; A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose; A male sexual partner who agrees to use a male condom with spermicide; A sterile sexual partner
Ki nem vehet részt
- Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
- Pregnancy:; positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
- Recent or active hepatitis A infection; test positive or have been treated for hepatitis B, hepatitis C, or HIV infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and/or opportunistic infection; and/or taking immunosuppressant medication
- Allergy to OPT101or any component of OPT101 formulation
- Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
- Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition; -
- QTc ≥ 450 msec on screening ECG
- Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score ≥ 12)
- Renal dysfunction: estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2, or need for hemodialysis or hemofiltration
- Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
- Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening
- Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening
- Participation in other interventional clinical trials
- Current hospital stay >72h
- Weight is over 250lbs
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Sepsis vagy community acquired pneumonia
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Denver Health and Hospital AuthorityDenver, Egyesült ÁllamokContact: Terra Miller, MSN, RNToborzás még nem indult
- Westchester Medical CenterValhalla, Egyesült ÁllamokContact: Lisa M Boswell, MSRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.
A teljes eredeti leírásKevesebb
This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.
A vizsgálat 2 csoportja
- 0.9% Sodium Chloride Injection USPPlacebo, összehasonlításként
Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.
Kezelés: Placebo
- OPT101A vizsgált kezelés
OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
- Kérdések a feltételekről
- Forrás: NCT06669403: ki vehet részt
- A regiszteradat frissítve
- 2026. november 18.